Acta Reumatol Port. 2020 Oct-Dec;45(4):259-264.
Systemic sclerosis (SSc) is a complex disorder of unknown etiology. The purpose of this study was to evaluate fibroblast growth factor-23 (FGF-23) serum levels in women with SSc compared with healthy controls and to examine a possible association between FGF-23 serum levels with the presence of calcinosis in SSc patients.
This cross-sectional study was performed in San Cecilio Hospital, Granada (Spain) from November 2017 to May 2019. Sixty-two women with SSc and 62 age and sex matched healthy controls were included in this study. FGF-23 serum concentration was evaluated by indirect enzyme-linked immunosorbent assay (ELISA).
There was no significant difference in FGF-23 levels between SSc patients and healthy controls (78.2 ± 60.5 vs. 80.3 ± 56.3 pg/mL, p= 0.662). Regarding the characteristics of the disease, we found a relationship between the values of FGF-23 and the presence of calcinosis. The levels of FGF-23 are higher in patients suffering from calcinosis (p= 0.028).
We observed the presence of higher levels of serum FGF-23 in SSc female patients with calcinosis. Therefore, FGF-23 could be a possible therapeutic target for future treatments.
系统性硬化症（SSc）是一种病因不明的复杂疾病。本研究旨在评估系统性硬化症女性患者与健康对照组之间成纤维细胞生长因子 23（FGF-23）血清水平，并探讨 FGF-23 血清水平与 SSc 患者钙沉积之间的可能关联。
本横断面研究于 2017 年 11 月至 2019 年 5 月在西班牙格拉纳达的 San Cecilio 医院进行。本研究纳入了 62 名 SSc 女性患者和 62 名年龄和性别匹配的健康对照组。通过间接酶联免疫吸附试验（ELISA）评估 FGF-23 血清浓度。
SSc 患者和健康对照组之间 FGF-23 水平无显著差异（78.2 ± 60.5 vs. 80.3 ± 56.3 pg/mL，p=0.662）。关于疾病特征，我们发现 FGF-23 值与钙沉积之间存在关系。患有钙沉积的患者 FGF-23 水平更高（p=0.028）。
我们观察到患有钙沉积的 SSc 女性患者血清 FGF-23 水平升高。因此，FGF-23 可能是未来治疗的一个潜在治疗靶点。
